CD274 and non-small cell lung carcinoma: Evidence from a recent meta-analysis indicates improved overall response rates with anti-PD-1/anti-PD-L1 therapy in NSCLC when used to treat chemotherapy-naïve patients as compared with patients previously treated with chemotherapy [20], highlighting the importance of identifying patients who will benefit from first-line anti-PD-1/anti-PD-L1 therapy.